Rifampicin and Letermovir as potential repurposed drug candidate for COVID-19 treatment: insights from an in-silico study
- 10 May 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in Pharmacological Reports
- Vol. 73 (3), 926-938
- https://doi.org/10.1007/s43440-021-00228-0
Abstract
Introduction Drug repurposing is the need of the hour considering the medical emergency caused by the COVID-19 pandemic. Recently, cytokine storm by the host immune system has been linked with high viral load, loss of lung function, acute respiratory distress syndrome (ARDS), multiple organ failure, and subsequent fatal outcome. Objective This study aimed to identify potential FDA approved drugs that can be repurposed for COVID-19 treatment using an in-silico analysis. Methods In this study, virtual screening of selected FDA approved drugs was performed by targeting the main protease (Mpro) of SARS-CoV-2 and the key molecules involved in the ‘Cytokine storm’ in COVID-19 patients. Based on our preliminary screening supported by extensive literature search, we selected FDA approved drugs to target the SARS-CoV-2 main protease (Mpro) and the key players of cytokine storm, TNF-α, IL-6, and IL-1β. These compounds were examined based on systematic docking studies and further validated using a combination of molecular dynamics simulations and molecular mechanic/generalized/Born/Poisson-Boltzmann surface area (MM/G/P/BSA) free energy calculations. Results Based on the findings, Rifampicin and Letermovir appeared as the most promising drug showing a very good binding affinity with the main protease of SARS-CoV-2 and TNF-α, IL-6, and IL-1β. However, it is pertinent to mention here that our findings need further validation by in vitro analysis and clinical trials. Conclusion This study provides an insight into the drug repurposing approach in which several FDA approved drugs were examined to inhibit COVID-19 infection by targeting the main protease of SARS-COV-2 and the cytokine storm. Graphic abstractKeywords
This publication has 28 references indexed in Scilit:
- Targeting the “Cytokine Storm” for Therapeutic BenefitClinical and Vaccine Immunology, 2013
- Optimization of parameters for molecular dynamics simulation using smooth particle‐mesh Ewald in GROMACS 4.5Journal of Computational Chemistry, 2011
- Confab - Systematic generation of diverse low-energy conformersJournal of Cheminformatics, 2011
- CurlySMILES: a chemical language to customize and annotate encodings of molecular and nanodevice structuresJournal of Cheminformatics, 2011
- The HIV protease inhibitor lopinavir/ritonavir (Kaletra) alters the growth, differentiation and proliferation of primary gingival epitheliumHIV Medicine, 2010
- GROMACS: Fast, flexible, and freeJournal of Computational Chemistry, 2005
- PRODRG: a tool for high-throughput crystallography of protein–ligand complexesActa crystallographica. Section D, Structural biology, 2004
- Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findingsThorax, 2004
- Crystal structure of the type-I interleukin-1 receptor complexed with interleukin-1βNature, 1997
- GROMACS: A message-passing parallel molecular dynamics implementationComputer Physics Communications, 1995